Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
“5 mg twice daily is used for extended therapy.(48)”
Method2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Self-citationOral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citationKonstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
“) should be considered after 6 months of therapeutic anticoagulation.(352,353) IIa A”
BackgroundInfluentialOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“5 mg twice daily for apixaban.(306,314) The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty.”
BackgroundKaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
“New England Journal Of Medicine, 382(17), 1599-1607.”
Self-citationAntithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Deep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Self-citationLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Self-citationKakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Lyman, G. H., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., Gates, L. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1118 · Cited by 713
“1% (5 mg).(58) Additional concerns with using these agents in patients with cancer include: unpredictable absorption and higher risk of GI bleeding in those with mucositis or other GI complications, altered metabolism in those with liver or renal impairment, drug interaction with hormonal and chemotherapeutic agents,…”
BackgroundFrontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
“apixaban, and edoxaban), and secondary prevention of deep venous thrombosis or pulmonary embolism (rivaroxaban and apixaban only) [119–128].”
BackgroundDirect Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Chen, A., Stecker, E., & A. Warden, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017559 · Cited by 666
Weitz, J. I., Fredenburgh, J. C., & Eikelboom, J. W. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.024 · Cited by 582
“In either case, the risk of recurrence is sufficiently high to justify continued anticoagulant therapy, particularly with the favorable benefit–risk profiles of reduced doses of apixaban or rivaroxaban for extended VTE treatment (39,40).”
BackgroundSelf-citationPrins, M. H., Lensing, A. W., Bauersachs, R., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Raskob, G. E., et al. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-21 · Cited by 551
Self-citationMazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402
“Bleeding did not differ between groups.(85) Recurrence rates with Edoxaban 60 mg were similar to the warfarin-treated group (post hoc analysis) (Table 5).”
ResultSelf-citationManagement of venous thrombo-embolism: an update
Konstantinides, S., & Torbicki, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu243 · Cited by 383
Venous Thromboembolism: Advances in Diagnosis and Treatment
Tritschler, T., Kraaijpoel, N., Le Gal, G., & Wells, P. S. (2018) · JAMA · doi:10.1001/jama.2018.14346 · Cited by 357
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 348
“Further, no meaningful differences were seen between male and female subjects in the primary efficacy or safety outcomes in the key phase III trials for apixaban [5, 6, 10, 11, 44].”
BackgroundGuidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
“Long term therapy trials with DOACs indicate that these medications will be very effective for long term therapy of VTE in patients with unprovoked VTE [40, 45, 111].”
BackgroundMethodSelf-citationHuisman, M. V., Barco, S., Cannegieter, S. C., Le Gal, G., Konstantinides, S. V., Reitsma, P. H., Rodger, M., Noordegraaf, A. V., & Klok, F. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.28 · Cited by 336
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
“In clinical trials of apixaban [5] and rivaroxaban [4, 8], a single-drug approach was employed without parenteral anticoagulation.”
BackgroundManagement of Pulmonary Embolism
Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.061 · Cited by 330
Khan, F., Rahman, A., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Eichinger, S., Kyrle, P. A., Becattini, C., et al. (2019) · BMJ · doi:10.1136/bmj.l4363 · Cited by 328
Self-citationMajeed, A., Ågren, A., Holmström, M., Bruzelius, M., Chaireti, R., Odeberg, J., Hempel, E.-L., Magnusson, M., Frisk, T., & Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-05-782060 · Cited by 326
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement
Juszczak, E., Altman, D. G., Hopewell, S., & Schulz, K. (2019) · JAMA · doi:10.1001/jama.2019.3087 · Cited by 324
Kumbhani, D. J., Cannon, C. P., Beavers, C. J., Bhatt, D. L., Cuker, A., Gluckman, T. J., Marine, J. E., Mehran, R., Messe, S. R., Patel, N. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.011 · Cited by 308
“Two DOACs, apixaban and rivaroxaban, offer the added advantage of reduced-intensity dosing in patients on indefinite anticoagulation whose VTE was $6 months ago (rivaroxaban 10 mg daily in EINSTEIN-CHOICE [Reduceddosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE] and apixaban 2.5 mg twice dail…”
InfluentialLopes, R. D., Alings, M., Connolly, S. J., Beresh, H., Granger, C. B., Mazuecos, J. B., Boriani, G., Nielsen, J. C., Conen, D., Hohnloser, S. H., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.04.008 · Cited by 290
“The Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy–Extended Treatment (AMPLIFY-EXT) study showed that extended use of apixaban was safe, with similar rates of major bleeds when compared with placebo.(26) Thus, the consistently favorable risk/benefit ratio o…”
Wang, X., Tirucherai, G., Marbury, T. C., Wang, J., Chang, M., Zhang, D., Song, Y., Pursley, J., Boyd, R. A., & Frost, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.628 · Cited by 286
“Apixaban is an oral, selective, direct reversible inhibitor of the coagulation factor Xa (FXa), approved in a number of countries for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery, for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fib…”
BackgroundIbrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13651 · Cited by 279
Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Kearon, C., & Akl, E. A. (2014) · Blood · doi:10.1182/blood-2013-12-512681 · Cited by 279
“5 mg or 5 mg twice-daily).(19,20) Extended treatment with low-molecular-weight-heparin (LMWH) is also very effective, and is more effective than a VKA in cancer patients.”
BackgroundAspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation · doi:10.1161/circulationaha.114.008828 · Cited by 262
“Siragusa, MD (13); Trieste, Italy- Medicina di Urgenza, Ospedale Cattinara: R.”
BackgroundSelf-citationNew Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
Sardar, P., Chatterjee, S., Chaudhari, S., & Lip, G. Y. H. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12799 · Cited by 267
Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review
Chopard, R., Albertsen, I. E., & Piazza, G. (2020) · JAMA · doi:10.1001/jama.2020.17272 · Cited by 244
Connors, J. M., Brooks, M. M., Sciurba, F. C., Krishnan, J. A., Bledsoe, J. R., Kindzelski, A., Baucom, A. L., Kirwan, B.-A., Eng, H., Martin, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.17272 · Cited by 251
Martin, K. A., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15358 · Cited by 249
Couturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
Pulmonary embolism: update on management and controversies
Duffett, L., Castellucci, L. A., & Forgie, M. A. (2020) · BMJ · doi:10.1136/bmj.m2177 · Cited by 232
Sharma, M., Cornelius, V. R., Patel, J. P., Davies, J. G., & Molokhia, M. (2015) · Circulation · doi:10.1161/circulationaha.114.013267 · Cited by 243
“In particular, dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA.”
BackgroundInfluentialAgeno, W., Mantovani, L. G., Haas, S., Kreutz, R., Monje, D., Schneider, J., van Eickels, M., Gebel, M., Zell, E., & Turpie, A. G. G. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00257-4 · Cited by 243
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., & Lipman, M. L. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090980 · Cited by 227
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Chatelain, C., Chatelain, B., Douxfils, J., Dogné, J.-M., & Mullier, F. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0898 · Cited by 213
“Additionally, it is being evaluated in the reduction of recurrent ischaemic events when added to antiplatelet therapy after acute coronary syndrome (4) and in the (extended) treatment of VTE (5, 6).”
BackgroundSterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Buckner, T., Diep, R., Fertrin, K. Y., Fogerty, A. E., Crestani, N. G., Gangaraju, R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0046 · Cited by 184
Overview of the New Oral Anticoagulants: Opportunities and Challenges
Yeh, C. H., Hogg, K., & Weitz, J. I. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.303397 · Cited by 189
“5-mg BID dose regimens were associated with rates of major bleeding similar to that with placebo.(11) Compared with warfarin, the rate of recurrent VTE with dabigatran was similar, but the rate of major bleeding was 50% lower with dabigatran than with warfarin (0.”
BackgroundSelf-citationDeep vein thrombosis: update on diagnosis and management
Kruger, P. C., Eikelboom, J. W., Douketis, J. D., & Hankey, G. J. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50201 · Cited by 188
Treatment of cancer-associated thrombosis
Lee, A. Y. Y., & Peterson, E. A. (2013) · Blood · doi:10.1182/blood-2013-04-460162 · Cited by 183
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., Pengo, V., Woller, S. C., Cortes-Hernandez, J., Connors, J. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.008 · Cited by 172
Carrier, M., Khorana, A. A., Zwicker, J. I., Noble, S., & Lee, A. Y. Y. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12338 · Cited by 174
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Chang, M., Yu, Z., Shenker, A., Wang, J., Pursley, J., Byon, W., Boyd, R. A., LaCreta, F., & Frost, C. E. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.633 · Cited by 171
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
Major Extremity Trauma Research Consortium (METRC) (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2205973 · Cited by 169
Kahn, S. R., & de Wit, K. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2116489 · Cited by 159
Woller, S. C., Stevens, S. M., Kaplan, D., Wang, T.-F., Branch, D. W., Groat, D., Wilson, E. L., Armbruster, B., Aston, V. T., Lloyd, J. F., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005808 · Cited by 166
“5 mg twice daily and apixaban 5 mg twice daily among patients receiving extended phase treatment of VTE, with a favorable relative risk for the outcome of cardiovascular death, stroke, and myocardial infarction when compared with placebo.(5) This pilot study was to randomize 200 TAPS patients to receive apixaban or wa…”
BackgroundNarouze, S., Benzon, H. T., Provenzano, D., Buvanendran, A., De Andres, J., Deer, T., Rauck, R., & Huntoon, M. A. (2017) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 164
Mueck, W., Schwers, S., & Stampfuss, J. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-10 · Cited by 165
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Mahé, I., Carrier, M., Mayeur, D., Chidiac, J., Vicaut, É., Falvo, N., Sanchez, O., Grangé, C., Monréal, M., López-Núñez, J. J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416112 · Cited by 194
Self-citationGuidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. E. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1319-y · Cited by 161
“Little is known about the use of DOACs in patients with an estimated CrCl\ 30 mL/min, as these patients were excluded from clinical trials comparing DOACs to warfarin for VTE treatment [14–20].”
BackgroundFrost, C. E., Byon, W., Song, Y., Wang, J., Schuster, A. E., Boyd, R. A., Zhang, D., Yu, Z., Dias, C., Shenker, A., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12541 · Cited by 160
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.12.002 · Cited by 153
“5 mg or 5 mg twice daily) or placebo.(371) Patients were eligible for inclusion if there was clinical equipoise regarding”
Self-citationSchrag, D., Uno, H., Rosovsky, R. P. G., Rutherford, C., Sanfilippo, K. M., Villano, J. L., Drescher, M. R., Jayaram, N. H., Holmes, C. E., Feldman, L. E., et al. (2023) · JAMA · doi:10.1001/jama.2023.7843 · Cited by 166
Reversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 161
Management of portal vein thrombosis in liver cirrhosis
Qi, X., Han, G., & Fan, D. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.36 · Cited by 145
Cohen, H., Arachchillage, D. J., Middeldorp, S., Beyer‐Westendorf, J., & Kadir, R. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13366 · Cited by 154
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1094 · Cited by 162
Self-citationGuntupalli, S. R., Brennecke, A., Behbakht, K., Tayebnejad, A., Breed, C., Babayan, L. M., Cheng, G., Ramzan, A. A., Brubaker, L. W., Corr, B. R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.7410 · Cited by 150
Tran, H. A., Gibbs, H. H., Merriman, E., Curnow, J. L., Young, L., Bennett, A., Tan, C.-W., Chunilal, S. D., Ward, C., Baker, R. I., et al. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50004 · Cited by 152
“5 Apixaban 2.5 mg twice daily is as efficacious as 5.0 mg twice daily for preventing VTE recurrence beyond 6 months, with no difference in major bleeding and a trend to have less CRNMB. 28 Likewise, ri-varoxaban 10 mg once daily is as efficacious as 20 mg once daily with a trend to have less major bleeding and CRNMB.…”
InfluentialKakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 138
Mazzolai, L., Ageno, W., Alatri, A., Bauersachs, R. M., Becattini, C., Brodmann, M., Emmerich, J., Konstantinides, S., Meyer, G., Middeldorp, S., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab088 · Cited by 153
Miller, C., Dorreen, A. P., Martel, M., Huynh, T. T., & Barkun, A. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 149
“3) Yamada et al,(50) 2015 Rivaroxaban (15) Warfarin 192, 197 d 100 0/22 (0), 0/55 (0) vs 0/19 (0) Schulman et al,(46) 2009 Dabigatran (300) Warfarin 163 d 2464 9/1274 (0.”
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve
Wang, T. Y., Svensson, L. G., Wen, J., Vekstein, A. M., Gerdisch, M., Rao, V. U., Moront, M. G., Johnston, D., Lópes, R. D., Chavez, A., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300067 · Cited by 144
Diagnosis and management of pulmonary embolism
Lapner, S. T., & Kearon, C. (2013) · BMJ · doi:10.1136/bmj.f757 · Cited by 144
Andreozzi, G. M., Bignamini, A. A., Davì, G., Palareti, G., Matuška, J., Holý, M., Pawlaczyk-Gabriel, K., Džupina, A., Юрьевич, С. Г., Didenko, Y. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016930 · Cited by 138
“2%, respectively).(10,13,14) Our study, however, has some limitations.”
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 127
“Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs for the first time in about 1 in 1000 persons each year, and the incidence rises with age to at least 5 in 1000 persons in those over the age of 80 years.1,2 About one-third of patients with symptomatic VTE pres…”
BackgroundMethodInfluentialSelf-citationElsebaie, M. A., van Es, N., Langston, A. A., Buller, H. R., & Gaddh, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14398 · Cited by 142
Self-citationBallestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 150
“5 mg) reduced the risk of recurrent VTE without increasing the MB rate compared to placebo [37].”
BackgroundResultVenous thromboembolism in cancer patients: an underestimated major health problem
Khalil, J., Bensaid, B., Elkacemi, H., Afif, M., Bensaïd, Y., Kebdani, T., & Benjaafar, N. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0592-8 · Cited by 126
“In patients with DVT of the leg and cancer, LMWH is suggested over VKA therapy (grade 2B).”
BackgroundInfluentialEffect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
Vakkalagadda, B. J., Frost, C. E., Byon, W., Boyd, R. A., Wang, J. J. J., Zhang, D., Yu, Z., Dias, C. S., Shenker, A., & LaCreta, F. P. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0157-9 · Cited by 133
Genetic risk factors for venous thromboembolism
Zöller, B., Svensson, P. J., Dahlbäck, B., Lind‐Halldén, C., Halldén, C., & Elf, J. L. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1804354 · Cited by 132
Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Antithrombotic Agents: New Directions in Antithrombotic Therapy
Chan, N., & Weitz, J. I. (2019) · Circulation Research · doi:10.1161/circresaha.118.313155 · Cited by 132
Self-citationCreager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.005 · Cited by 145
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
Flaujac, C., Delavenne, X., Quenet, S., Horellou, M., Laporte, S., Siguret, V., Lecompte, T., & Gouin‐Thibault, I. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0470 · Cited by 116
“Phase III clinical trials with apixaban for treatment of venous thromboembolism have also been completed (4, 5).”
BackgroundGorog, D. A., Gue, Y. X., Chao, T., Fauchier, L., Ferreiro, J. L., Huber, K., Konstantinides, S., Lane, D. A., Marín, F. R., Oldgren, J., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1750385 · Cited by 121
Olaf, M. F., & Cooney, R. R. (2017) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2017.06.003 · Cited by 138
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 117
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
Gelosa, P., Castiglioni, L., Tenconi, M., Baldessin, L., Racagni, G., Corsini, A., & Bellosta, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.016 · Cited by 121
Long-term treatment of venous thromboembolism
Kearon, C., & Kahn, S. R. (2020) · Blood · doi:10.1182/blood.2019002364 · Cited by 127
Safety and effectiveness of apixaban compared to warfarin in dialysis patients
Reed, D. R., Palkimas, S., Hockman, R. H., Abraham, S., Le, T. M., & Maitland, H. S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12083 · Cited by 115
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Self-citation
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.